Bajaj Healthcare SEC nod boosts CNS pipeline in 2024

What happened and why it matters

Bajaj Healthcare has flagged a key regulatory step in its central nervous system (CNS) pipeline after receiving a recommendation from the Subject Expert Committee (SEC) (Neurology and Psychiatry) under the Central Drugs Standard Control Organisation (CDSCO). The recommendation is to conduct Phase III clinical trials for Suvorexant tablets, which the company described as a first-of-its-kind nod in India for Suvorexant. Separately, company updates also referenced Phase III trial approval for Cenobamate tablets, a drug used in epilepsy management. Together, these developments add to Bajaj Healthcare’s late-stage clinical pipeline at a time when it is also reporting revenue growth and higher profitability. For investors, the key point is that Phase III trials are typically a final major clinical step before a company can pursue full regulatory clearance for marketing.

SEC-CDSCO recommendation for Suvorexant Phase III

Bajaj Healthcare said it received the SEC (Neurology and Psychiatry) recommendation to initiate Phase III clinical trials for Suvorexant tablets. The strengths mentioned in the provided disclosures include 5 mg, 10 mg, 15 mg and 20 mg, and another disclosure also referenced 50 mg among the strengths. The company positioned this as a pioneering step, stating it is the first in India to receive such a recommendation for Suvorexant. A separate filings digest post cited October 4, 2025 as the date of the SEC approval for Phase III trials for Suvorexant. The SEC recommendation is part of the CDSCO review process for clinical trial permissions in India.

Cenobamate Phase III trial clearance and CNS portfolio focus

Alongside Suvorexant, Bajaj Healthcare updates also pointed to progress on Cenobamate tablets. The company communication referenced DCGI approval for Phase III trials for Cenobamate tablets, describing it as a boost to the CNS portfolio. In market coverage around this development, Cenobamate was described as an anti-seizure medicine used for partial onset seizures in adults. The approval to run Phase III studies is an enabling step in the pathway toward a potential commercial launch, subject to the outcome of trials and subsequent regulatory processes. The sequence described in the coverage underlines why the CNS segment has become a focus area in the company’s pipeline narrative.

Stock reaction: March 19 move after Cenobamate update

Bajaj Healthcare shares rallied sharply on March 19, 2024, after the Phase III clinical trial approval news around Cenobamate. Reports said the stock jumped nearly 10% to a fresh 52-week high of Rs 740 per share. Later, the stock was cited at Rs 731, still up about 8% from the previous close. The move highlighted how sensitively smaller pharma names can react to late-stage regulatory and clinical updates, particularly when the product addresses a large therapy area such as epilepsy. The price action also reflected that investors tend to treat Phase III permissions as a significant milestone, even though commercial outcomes depend on successful trials and further approvals.

Q2 FY26 financial snapshot: growth and profitability

In addition to pipeline updates, Bajaj Healthcare’s Q2 FY26 numbers were highlighted in the provided information set. Q2 FY26 revenue was reported at ₹1,479.1 million, up 11.1% year-on-year. EBITDA for the quarter was ₹286.0 million, with an EBITDA margin of 19.1%. Profit after tax (PAT) from continuing operations was ₹124.5 million, up 49.2% year-on-year. The same updates also said API exports grew 66.9% year-on-year in Q2. Management commentary referenced a focus on margin expansion and a higher mix of high-margin products.

Filings and R&D indicators cited by the company

Beyond clinical trial permissions, the company also shared progress on regulatory filings that can support longer-term product launches. It filed two new CEPs, taking total CEP filings to 10, with 7 approved and 3 under review, as per the information provided. Cumulative DMF filings were stated at 60 globally. These filing metrics matter for an API and formulations player because approvals and dossiers influence how quickly products can move into regulated markets. The company also pointed to a strategic push in regulated markets and continued R&D investments for sustainable growth.

Key facts at a glance

Market impact: what investors are tracking

For the market, two strands are moving together in this story: clinical pipeline momentum and operating performance. The regulatory milestones around Suvorexant and Cenobamate signal continued activity in the CNS segment and can keep investor attention on the company’s product development roadmap. At the same time, Q2 FY26 numbers suggest improving profitability, with PAT growth outpacing revenue growth in the reported figures. The company’s emphasis on regulated market expansion, and its filing counts for CEPs and DMFs, add context on how it is building a broader approvals pipeline. However, the practical impact of Phase III approvals ultimately depends on clinical outcomes and subsequent regulatory decisions.

Why the developments matter for Bajaj Healthcare

Phase III trial recommendations and approvals are significant because they represent late-stage progress in the drug development cycle and can broaden a company’s future launch options. In parallel, margin and export growth can indicate whether the business has near-term operating strength to fund development and filings. In Bajaj Healthcare’s case, the combination of Q2 profitability metrics, export growth, and regulatory filings provides multiple datapoints for investors evaluating execution. The sharp stock reaction on March 19, 2024 also shows how quickly sentiment can shift on regulatory news. The next concrete milestones, based on the information provided, remain tied to Phase III trial execution and any subsequent announcements from the company or regulators.

Conclusion

Bajaj Healthcare’s updates combine a regulatory step for Suvorexant Phase III trials, Phase III trial clearance for Cenobamate, and a Q2 FY26 performance snapshot showing revenue growth and higher PAT. The company has also highlighted CEP and DMF filing progress and a strategy focused on regulated markets and margin expansion. The key near-term watchpoints are the conduct and progress of the Phase III studies and any follow-on regulatory communications tied to these programs.